Cullinan Management Advances SLE Treatment with FDA Trial

Cullinan Management ( (CGEM) ) just unveiled an announcement.

Cullinan Therapeutics has received FDA clearance to proceed with a Phase 1 clinical trial of CLN-978, a novel bispecific T cell engager, for treating systemic lupus erythematosus (SLE). This trial aims to evaluate the safety and efficacy of CLN-978 in patients with moderate to severe SLE, offering a potentially groundbreaking approach to addressing unmet medical needs in autoimmune diseases. The study will explore various dosing phases to assess the optimal treatment strategy, highlighting Cullinan’s commitment to advancing therapeutic solutions in autoimmune conditions.

See more insights into CGEM stock on TipRanks’ Stock Analysis page.